$1.82
+0.11 (+6.43%)
Open$1.77
Previous Close$1.71
Day High$1.87
Day Low$1.73
52W High$42.75
52W Low$21.38
Volume—
Avg Volume657.7K
Market Cap176.38M
P/E Ratio48.55
EPS$0.79
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+2,056.0% upside
Current
$1.82
$1.82
Target
$39.24
$39.24
$29.92
$39.24 avg
$50.68
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 18.06M | 17.10M | 17.57M |
| Net Income | 3.97M | 3.03M | 3.72M |
| Profit Margin | 22.0% | 17.7% | 21.2% |
| EBITDA | 5.85M | 5.37M | 5.78M |
| Free Cash Flow | 3.20M | 3.54M | 3.04M |
| Rev Growth | +2.4% | +6.2% | +3.3% |
| Debt/Equity | 0.94 | 1.00 | 0.76 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |